Moderate to severe treatment-resistant ulcerative colitis: Integrin inhibitor etrolizumab leads to clinical remission;Mäßige bis schwere, therapierefraktäre Colitis ulcerosa: Integrinhemmer Etrolizumab führt in klinische Remission

Arzneimitteltherapie

Volumn 32, Issue 11, 2014, Pages 309-318

  Kreutzkamp, Barbara ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE SEVERITY; NOTE; ULCERATIVE COLITIS;

EID: 84916595050     PISSN: 07236913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (2)

1. Vermeire S, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384:309-18.
2. Armuzi A, et al. Etrolizumab in moderate-tosevere ulcerative colitis. Lancet 2014; Epub 9. Mai 2014.